80 results about "Proteus mirabilis" patented technology

The invention discloses a strain of lactobacillus plantarum, which is named as L.plantarum ZW1, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) 26685. The lactobacillus plantarum provided by the invention is a lactic acid bacterium with relatively strong broad-spectrum inhibition capability, and after the interference of organic acid and hydrogen peroxide is eliminated and protease treatment verification is carried out, the strain is determined to have relatively strong bacteriocin production capability. Probiotic performance evaluation shows that the strain has good digestive tract fluid tolerance, and the L.plantarum CGMCC26685 has good intestinal tract probiotic characteristics, can significantly enrich mouse intestinal flora in an in-vitro intestinal flora fermentation model, increase the relative abundance of the phylum of thick-walled bacteria, reduce the relative abundance of the phylum of proteobacteria, proteusbacillus and shigella, and improve the intestinal tract fluid resistance of mice. The number of flora OTU is obviously higher than that of lactobacillus rhamnosus LGG and lactobacillus plantarum L.plantarum PL4 group which does not produce bacteriocin, and the Chao1 index, the Shannon index and the Simpson index are obviously improved compared with those of a control group. It is shown that the L.plantarum CGMCC26685 has good intestinal tract beneficial activity, and has the potential of further performance excavation and application expansion.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention belongs to the technical field of bacteriophages, and discloses a proteus mirabilis bacteriophage PF05, a bacteriophage composition thereof and application of the proteus mirabilis bacteriophage PF05, the proteus mirabilis bacteriophage PF05 is preserved in China General Microbiological Culture Collection Center (CGMCC) on March 22, 2024, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.9687. The preservation number is CGMCC (China General Microbiological Culture Collection Center) The bacteriophage is resistant to high temperature, wide in lysis spectrum, high in storage stability and good in gastric acid tolerance, can keep activity in the stomach for a long time, and has a good prevention and treatment effect on infection of proteus mirabilis in the intestines and the stomach. The compound can be prepared into medicines, environment disinfectants, feeds, water additives and the like for preventing and treating proteus mirabilis for application, not only effectively prevents and treats propagation of proteus mirabilis, but also has the effects of reducing the death rate of chicken flocks, reducing digestive tract infection of the chicken flocks, avoiding diarrhea of the chicken flocks and improving the resistance of the chicken flocks, and has a very good market application prospect.

The invention belongs to the field of molecular biology detection, particularly relates to detection of blood flow infection related pathogens, and more particularly relates to detection and distinguishing of at least four pathogens in burkholderia cepacia, streptococcus mirabilis, staphylococcus capitis, staphylococcus coriolis, proteus mirabilis and staphylococcus haemolyticus. According to the combined detection composition provided by the invention, different pathogens are detected by mainly utilizing a multiple fluorescent PCR analysis method and detecting target spots on the different pathogens; therefore, at least four pathogens in burkholderia cepacia, streptococcus mitis, staphylococcus capitis, staphylococcus coriolis, proteus mirabilis and staphylococcus haemolyticus are detected and distinguished in a single-tube reaction system at the same time, and the detection efficiency is improved. The composition disclosed by the invention is high in detection sensitivity, and the detection sensitivity reaches 200 copies / mL; the reagent / kit provided by the invention adopts a UNG enzyme and dUTP anti-pollution system, so that the accuracy of the detection effect can be guaranteed.

The invention relates to a bacteriophage, in particular to a cross-host multivalent bacteriophage and preparation and application of a bacteriostatic agent of the bacteriophage, the multivalent bacteriophage is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2026045. The salmonella bacteriophage CCTCC NO: M 2026045 is found for the first time, is a multivalent bacteriophage, can cross-host infect and split multiple important livestock and poultry intestinal pathogens such as salmonella, escherichia coli, shigella, klebsiella pneumoniae and proteus mirabilis, solves the problem of narrow host range of a single bacteriophage, and improves the prevention and control efficiency. By inhibiting the overgrowth of the gram-negative pathogenic bacteria, the intestinal microecological balance can be regulated, so that the aim of effective prevention and control is fulfilled.

The present application relates to the field of pharmaceutical chemistry, and specifically discloses a emodin mannich base, a preparation method and application thereof. The emodin mannich base has a structure as shown in formula I, the structure is simple, has strong in-vitro antimicrobial activity, especially high inhibitory activity to staphylococcus aureus, bacillus subtilis, micrococcus luteus, escherichia coli, proteus vulgaris, pseudomonas aeruginosa, shigella dysenteriae, salmonella typhimurium and other bacteria, and candida utilis, candida albicans, saccharomyces cerevisiae, monascus and other fungi, and can be used for preparing antibacterial and / or antifungal drugs.

The invention discloses a quadruple PCR (Polymerase Chain Reaction) detection primer combination for detecting diarrhea pathogenic bacteria of young deer and application, and belongs to the technical field of biology. The quadruple PCR detection primer combination for detecting the diarrhea pathogenic bacteria of the young deer comprises an escherichia coli primer pair as shown in SEQ ID NO.1-2, a klebsiella pneumoniae primer pair as shown in SEQ ID NO.3-4, a salmonella primer pair as shown in SEQ ID NO.5-6 and a proteus mirabilis primer pair as shown in SEQ ID NO.7-8. The invention further discloses a kit for detecting the diarrhea pathogenic bacteria of the young deer. The multiple PCR detection method is established by using the specific genes of the main pathogenic bacteria of the diarrhea of the baby deer, so that the pathogenesis of the diarrhea of the baby deer can be quickly and accurately detected, the detection efficiency of epidemic diseases is greatly improved, and the method has important significance in preventing and treating bacterial diarrhea of the baby deer.

The present invention discloses a meso-diaminopimelate dehydrogenase mutant of Proteus vulgaris and its application, belonging to the technical field of bioengineering. The present invention constructs a PvDAPDH mutant, which, compared with the wild enzyme, can catalyze the synthesis of D-amino acids from a variety of aromatic α-ketoacids, and the stereoselectivity can reach 95%. The triple mutant W121I / H227I / R181S of pvDAPDH constructed in the present invention shows good compatibility with different large-volume aromatic α-ketoacid substrates, can simultaneously catalyze the conversion of most aromatic α-ketoacid substrates into D-amino acids, shows high catalytic activity towards 2-oxo-4-phenylbutyric acid, and the yield of the product D-homophenylalanine reaches 2.1 g / L. The present invention effectively expands the toolbox for the biosynthesis of aromatic D-amino acids.

The invention described herein pertains to a novel biological healing agent specifically formulated for use in mortar, aiming to enhance the longevity and durability of construction materials. Tradicional mortar and concrete structures are susceptible to cracking and degradation over time. This inventions seeks to address these problems by integrating a bacterial-based solution comprising Proteus mirabilis and an organic calcium source that promotes self-healing when cracks occur.

The invention provides application of bacillus subtilis JY166 in preparation of a microecological preparation or feed for soft-shelled turtles, and belongs to the technical field of aquatic animal breeding. The bacillus subtilis JY166 is separated from intestinal tracts of soft-shelled turtles, is identified to have the following characteristics that the bacillus subtilis JY166 is gram-positive, is rod-shaped, has spores, can grow in the environment with the temperature of 15-40 DEG C, the pH value of 6-11 and the NaCl concentration of less than or equal to 3wt%, and has a remarkable antagonistic effect on common proteusbacillus vulgaris, serratia marcescens and proteusbacillus penneri which are common in soft-shelled turtle culture. The invention further provides a soft-shelled turtle microecological preparation and feed containing the strain, double inhibition of pathogenic bacteria in soft-shelled turtle intestinal tracts and aquaculture water can be achieved through water application or feed addition, the micro-ecological environment is improved, disease occurrence is reduced, the requirement for green development of fishery is met, and good application prospects are achieved.

The invention belongs to the technical field of microorganisms, and particularly relates to a novel strain of brevibacterium and application thereof. The strain is separated from rapana venosa, is a new species of Brevibacterium, is named as Brevibacterium sp. M-17, is registered and preserved in the China Center for Type Culture Collection (CCTCC), and has the preservation number of CCTCC NO: M 20241860. The Brevibacterium sp. M-17 strain disclosed by the invention has obvious bacteriostatic activity on bacillus subtilis, escherichia coli, shewanella, enterobacter aerogenes, staphylococcus aureus and proteus vulgaris, has obvious antioxidant activity, has alpha-glucosidase inhibitory activity, can generate gelatinase, cellulase and amylase, and can be used for preparing an anti-inflammatory agent. The strain can be applied to preparation of bacteriostatic agents, antioxidants, alpha-glucosidase inhibitors, gelatinase, cellulase and amylase, can also be applied to industrial production instead of the bacteriostatic agents, the antioxidants, the gelatinase, the cellulase and the amylase in a viable bacterium form, and has good development and application prospects.

The application discloses a cadmium-resistant proteus mirabilis and application thereof in treatment of composite pollution environment. Priestia megaterium The application provides a PBAT-degrading bacterium, i.e., a proteus mirabilis (S261-3) strain, which can grow at a temperature of 10-50 DEG C and has certain salt and cadmium resistance, and can grow normally in a high-salt or high-cadmium concentration range. Meanwhile, the S261-3 strain has a good PBAT-degrading effect, and can degrade PBAT under cadmium stress, and can be used for degrading plastic pollutants in cadmium-polluted soil. The microbial strain provided by the application has stronger adaptability to a polluted environment, meets the repair demand of a composite pollution site, can be used for comprehensive treatment of microplastic and heavy metal composite pollution, is helpful to improving soil quality and improving land utilization efficiency, and has important practical significance for soil composite pollution repair.

The invention belongs to the technical field of microorganisms, and particularly discloses application of proteusbacillus vulgaris Ch8 to reduction of cadmium content of ligusticum wallichii and promotion of accumulation of medicinal components of ligusticum wallichii. The method comprises the following steps: a bacterial suspension of the Proteus sp. Ch8 is applied to rhizosphere soil of ligusticum wallichii, and cultivation and planting are carried out. According to the application, the proteusbacillus vulgaris Ch8 is applied to ligusticum wallichii planting, so that the cadmium content of medicinal parts can be remarkably reduced, and meanwhile, accumulation of medicinal components such as ferulic acid, ligustilide and senkyunolide I of ligusticum wallichii is promoted. The application is simple and convenient to operate, healthy and safe, the toxicity of cadmium can be effectively reduced, and the efficacy quality and economic value of ligusticum wallichii are improved.

The present invention relates to a method for treating Gram-negative bacteria that are resistant to colistin (MIC > 50 mg / mL), an antibacterial compound, excluding those of the genera Burkholderia, Proteus, and Serratia, comprising contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of formula I, dissolved or dispersed at a concentration of about 0.01 to about 15 mg / mL, and irradiating the contacted bacteria with light of a wavelength of about 500 nm to about 600 nm for a period of about 1 to about 10 minutes, at a concentration of about 16 to about 160 J / cm². 2 The aim is to create a method that involves obtaining a certain amount of light to treat and kill irradiated bacteria. [Formula 1] JPEG2026511692000028.jpg5864 (where X, R 1 , R 2 (and M+ are defined herein)

The invention belongs to the technical field of bioengineering, and particularly relates to chondroitin sulfate ABC I lyase as well as a mutant and application thereof. The present invention provides a chondroitin sulfate ABC I lyase CSABC I-NS1, and a mutant CSABC I-NS1-muout of the enzyme, and a preparation method of the chondroitin sulfate ABC I lyase CSABC I-NS1-muout. The chondroitin sulfate ABC I lyase CSABC I-NS1 is derived from Proteus mirabilis, a mutant CSABCI-NS1-E502F with high enzyme activity and high stability is obtained after site-specific mutagenesis, the specific enzyme activity of the mutant CSABCI-NS1-E502F is 72.53 U / mg, and the half-life period of the mutant CSABCI-NS1-E502F at 37 DEG C is 96.80 h; and the method has important significance for realizing biological industrial preparation of low-molecular-weight chondroitin sulfate.

The present invention provides a lung squamous cell carcinoma patient immunotherapy effect prediction device, which comprises a detection unit and a data analysis unit, the detection unit extracts 9 types of intra-tumor bacteria as characteristic intra-tumor bacteria based on 16S rRNA sequencing data of a lung squamous cell carcinoma patient tumor puncture sample; the data analysis unit is used for constructing a data model for predicting the curative effect of immunotherapy on the basis of 16S rRNA sequencing data of tumor puncture samples of the characteristic intra-tumor bacteria and lung squamous cell carcinoma patients; the characteristic intra-tumorous bacteria comprise a plasmobacterium actinomycetes genus, an anaerobic bacillus genus, a kantobacterium genus, a Vinci bacterium genus, a kocuria genus, a freshwater bacterium genus, a microbacterium genus, an achromobacter genus and a proteus genus; the prediction device can predict whether immunotherapy of lung squamous cell carcinoma patients is effective or not, screening and hierarchical management can be conducted on the patients before treatment, and therefore individualized medication is guided, and the curative effect is improved.

The present invention discloses a membrane-bound L-amino acid deaminase mutant and its application. The membrane-bound L-amino acid deaminase mutant is obtained by mutating the wild-type PM1 enzyme derived from Proteus mirabilis. The amino acid sequence of the wild-type PM1 enzyme is shown in SEQ ID No. 1, and the mutation mode is any one of the following: (1) G259W; (2) D340N. The PM1 enzyme mutant of the present invention is obtained by mutating the wild-type PM1 enzyme derived from Proteus mirabilis. The turnover numbers of the whole cells of the two mutants G259W and D340N for catalyzing L-phenylalanine are increased by 1.3 times and 1.2 times respectively compared with that of the WT.

The invention belongs to the field of molecular biology detection, particularly relates to detection of diarrhea-related pathogens, and more particularly relates to detection of at least four of morganella morganii, provingue, proteus mirabilis, enterobacter aerogenes and aeromonas caviridis. The composition disclosed by the invention is higher in detection sensitivity (up to 500 copies / mL), good in specificity and more accurate in detection, and can provide sufficient basis for rapid detection and exclusion of infection of different pathogens, shorten the judgment time of diarrhea inducements and accelerate implementation of countermeasures.

The invention discloses cadmium-resistant P.megaterium and an application of the cadmium-resistant P.megaterium in treatment of a combined polluted environment. The invention provides a PBAT (poly (butyleneadipate-co-terephthalate)) efficient degradation bacterium, namely, a Pristia megaterium S261-3 strain, and the strain can grow at the temperature of 10-50 DEG C, has certain salt and cadmium resistance, and can normally grow in a relatively high salt or cadmium concentration range. Meanwhile, the S261-3 strain has a good degradation effect on PBAT, can also degrade PBAT under cadmium stress, and can be used for degrading plastic pollutants in cadmium-polluted soil. The microbial strain provided by the invention has stronger adaptability to polluted environment, meets the repair requirement of a combined pollution site, can be used for comprehensive treatment of micro-plastic and heavy metal combined pollution, is beneficial to improvement of soil quality and improvement of land utilization efficiency, and has important practical significance for soil combined pollution repair.

The present invention relates to a vaccine composition for prophylactic use against Streptococcus pneumoniae infections. This composition contains inactivated bacteria of Escherichia coli, Morganella morganii, Proteus mirabilis, Klebsiella pneumoniae and Enterococcus faecalis and preferably dextran and an aluminum compound as adjuvant.

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron-emitting mannitol analogue, [18F]fluoromannitol ([18F]FMtl), are rapidly taken up by gram-positive and gram-negative bacteria such as E. coli, S. aureus, A. baumannii, S. epidermis, P. mirabilis, S. enterica, K. pneumonia, E. faecium, E. cloacae, and M. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.

The invention belongs to the field of microorganisms, and relates to lactobacillus rhamnosus and application thereof. The lactobacillus rhamnosus KC3 is separated from Xinjiang healthy bactrian camel milk, and the lactobacillus rhamnosus KC3 has the activity of inhibiting various pathogenic bacteria such as escherichia coli, klebsiella pneumoniae, salmonella, proteus mirabilis, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and streptococcus agalactiae. The metabiotics of the strain can enhance the sensitivity of pathogenic bacteria such as escherichia coli and staphylococcus aureus to antibiotics such as beta-lactam antibiotics, and can synergistically enhance the antibacterial effect of the beta-lactam antibiotics to the pathogenic bacteria such as escherichia coli, staphylococcus aureus, CRE or MRSA. The lactobacillus rhamnosus KC3 metagen can also destroy cell walls of pathogenic bacteria such as escherichia coli, staphylococcus epidermidis, CRE or MRSA and the like, and the formation of bacterial biofilms is inhibited.

The application provides a preparation method of earthworm antibacterial crude protein and belongs to the technical field of biotechnology. The technical scheme comprises the following steps: stimulating earthworms with tea dregs liquid, homogenizing the earthworms, centrifugal separation, and obtaining earthworm antibacterial crude protein after freeze-drying. The earthworm species that can be used in the application include Octochaetus porrectus, Metaphire cummingi, Drawida japonica, Drawida hupehensis or Allolobophora clavata. The obtained earthworm antibacterial crude protein can inhibit Pseudomonas aeruginosa, Enterobacter cloacae, Proteus vulgaris and Serratia marcescens after being dissolved in sterile water. The application has the advantages of wide raw material sources, simple preparation method and the like, and has potential values in aspects of livestock breeding, medical treatment and health care and the like.

The invention discloses a biological prevention and control method for guava root-knot nematodes, and belongs to the technical field of biological prevention and control of diseases and insect pests, and the biological prevention and control method for guava root-knot nematodes comprises the following steps: adding a complex microbial inoculant into excrement, the method comprises the following steps: fermenting a mixture of pseudomonas fluorescens ACCC 03936, pseudomonas fluorescens ACCC 01144, pseudomonas aeruginosa ACCC 60044 and proteusbacillus vulgaris ACCC 11766 to obtain a biological fermentation solution, applying the biological fermentation solution twice in a young psidium guajave shoot germination period and a nematode infection peak period, and performing conventional field management after the biological fermentation solution is applied. The method can effectively prevent and treat guava root-knot nematode infection, is ecological and environment-friendly, is simple and convenient, and can obviously improve the yield and quality of guavas.

The invention belongs to the field of molecular biology detection, and particularly relates to a composition and a method for detecting and distinguishing proteus mirabilis, klebsiella pneumoniae, escherichia coli and a fosfomycin drug-resistant gene GlpT gene, a fluoroquinolone drug-resistant gene GyrA gene and a fluoroquinolone drug-resistant gene GyrB gene, and application of the composition and the method. The joint detection composition provided by the invention can realize rapid detection of three pathogen target genes and three drug-resistant gene segments on pathogens in one tube of reaction liquid by utilizing a PCR detection technology, and has the characteristics of short time, high sensitivity, good specificity and the like. According to the invention, pathogenic bacteria can be accurately detected, and the mixed infection condition of bacteria can be analyzed, so that the effect of accurate medication is achieved, the use of antibiotics is reduced, and the cost is saved.

The invention belongs to the technical field of biological medicine, and discloses an auxiliary marker for diagnosing atherosclerotic plaque instability and acute coronary syndrome and application of the auxiliary marker. The auxiliary marker is selected from at least one of the following: a) proteus mirabilis; b) extracellular vesicles derived from proteus mirabilis; and c) HpmA in the extracellular vesicles. The auxiliary marker is used for preparing a product for diagnosing, screening or evaluating atherosclerotic plaque instability and / or acute coronary syndrome. It is proved that proteus mirabilis is remarkably enriched in ACS patients, and extracellular vesicles carrying HpmA penetrate through intestinal barriers and are enriched at atherosclerotic plaques. The vesicles inhibit FAK / SRC signal channels through HpmA, induce phenotypic transformation of VSMC and promote plaque instability, and an action target and a screening model are provided for drug development. Detection is carried out through non-invasive samples such as excrement or blood, and the method is easy to popularize.

The invention discloses an L-amino acid deaminase mutant and application thereof. The invention verifies that the L-amino acid deaminase derived from proteus haunhai has the capability of catalyzing L-glutamic acid to generate alpha-KG for the first time. Through protein three-dimensional structure simulation and the like, it is predicted that related sites possibly influencing catalysis and combination are I64, G257, Q278 and M440, site-saturated mutation is carried out, and a mutant and engineering bacteria for efficient catalytic synthesis of alpha-KG are obtained. Compared with a wild type, the catalytic activity of the mutant for catalyzing L-glutamic acid to generate alpha-ketoglutaric acid is remarkably improved, and the mutant has a wide prospect of large-scale industrial application.

This invention discloses a cholesterol-regulated bio-hybrid nanoparticle formulation, its preparation method, and its application, belonging to the field of biomedical technology. The preparation method includes: preparing a gold nanoparticle solution; mixing the gold nanoparticle solution with a photosynthetic bacteria culture to obtain a PSB@GNP complex; mixing the PSB@GNP complex with a Proteus mirabilis culture to obtain a PM-PSB@GNP core solution; and modifying the PM-PSB@GNP core solution with a coating solution followed by spray drying to obtain the bio-hybrid nanoparticle formulation EC-PM-PSB@GNP. The preparation process of this invention is simple and controllable, requiring no complex or precise equipment. Oral administration is convenient, resulting in high patient compliance. Compared to traditional chemical drugs and injectable formulations, it significantly reduces systemic toxicity and environmental pollution risks, while also reducing treatment procedures and medication costs, achieving efficient, safe, and precise colorectal cancer treatment and meeting clinical application needs.

The invention discloses L-amino acid deaminase as well as a mutant and application thereof. The invention verifies that the L-amino acid deaminase derived from proteus haunhai has the capability of catalyzing L-glutamic acid to generate alpha-KG for the first time. Through protein three-dimensional structure simulation and the like, it is predicted that related sites possibly influencing catalysis and combination are I64, G257, Q278 and M440, site-saturated mutation is carried out, and a mutant and engineering bacteria for efficient catalytic synthesis of alpha-KG are obtained. Compared with a wild type, the yield of alpha-KG generated through catalysis of the mutant LAAD-phRK is increased by 4.53 times. 1.5 g / L of LAAD-phRK whole cells react in a reaction system containing 10 mM of L-glutamic acid and 10 mM of calcium ions at the temperature of 30 DEG C and the pH value of 8.0 for 8 h, L-glutamic acid with the concentration of 6 mM or above can be converted, the molar yield of alpha-KG is 60% or above, and the LAAD-phRK whole cells have wide prospects in large-scale industrial application.